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Abstract 
Birt–Hogg–Dubé (BHD) syndrome, a hereditary renal cancer syndrome caused by mutations in the folliculin (FLCN) 
gene, is characterized by the presence of fibrofolliculomas, pulmonary cysts, spontaneous pneumothorax, and renal 
cell carcinoma (RCC). Few BHD syndrome cases have been reported in Asian countries, and cutaneous presenta-
tions are relatively rare in Asian patients. Asian BHD patients may be misdiagnosed due to their atypical manifesta-
tions. Here, we report two Chinese BHD patients with novel FLCN mutations (c.946-947delAG in exon 9 and c.770-
772delCCT in exon 7). Both of them had RCC and spontaneous pneumothorax without fibrofolliculomas. In patients 
with RCC and pulmonary cysts but without cutaneous lesions, screening for mutations in the FLCN gene should be 
performed, especially for those with a family history of RCC or pulmonary cysts (pneumothorax).
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Background
Birt–Hogg–Dubé syndrome (BHD, OMIM #135150) 
is a rare autosomal dominant hereditary disease first 
described by Birt et al. in 1977 [1]. This syndrome is char-
acterized by the presence of fibrofolliculomas (FFs), pul-
monary cysts, spontaneous pneumothorax, and renal cell 
carcinoma (RCC) [2]. Germline mutations in the follicu-
lin (FLCN) gene mapped to chromosome 17p11.2 were 
identified in BHD patients in 2002 [3]. FLCN mutations 
have also been detected in isolated familial spontaneous 
pneumothorax and familial clear cell carcinoma [4]. FLCN 
is considered a tumor suppressor gene and interacts with 
the mammalian target of rapamycin (mTOR) and adeno-
sine monophosphate-activated protein kinase (AMPK) 
signaling pathways. The spectrum of FLCN gene muta-
tions has been outlined in several reports and has been 
summarized in a database (http://www.lovd.nl/flcn) [5]; 
however, the genotype-phenotype associations between 
the FLCN gene and BHD syndrome are not well known.
Most BHD cases have been identified in Caucasians. 
Only several reports of compiled BHD cases in the lit-
erature have been from Asia, and most of them have 
been from Japan [6–8]. Many of the BHD patients from 
Asia have not had all symptoms (FFs, pulmonary cysts, 
spontaneous pneumothorax, and RCC) [8]. The most 
life-threatening manifestation of BHD syndrome is renal 
cancer, which is present in 27%–41% of patients [2, 9, 
10]. RCCs in BHD patients can be multiple or bilateral 
and include various histopathologic types, such as hybrid 
oncocytic tumor, chromophobe RCC, clear-cell RCC, 
oncocytoma, and papillary RCC [10, 11].
Here, we report two Chinese BHD patients with two 
novel germline FLCN mutations. Analysis of these 
patients was approved by the Medical Ethics Commit-
tee of Peking University First Hospital. Written informed 




A 54-year-old man was found to have asymptomatic, 
bilateral renal tumors by ultrasonography and computed 
tomography (CT) (Fig.  1a, b). CT scan also showed left 
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pneumothorax (Fig.  1c). No apparent cutaneous lesions 
were found by careful inspection and palpation of the 
skin. The patient had a history of spontaneous pneumo-
thorax at the age of 30. His son also had a history of spon-
taneous pneumothorax at the age of 17. Open bilateral 
and partial nephrectomies were performed. Histopatho-
logic examination revealed that the tumor in the left 
kidney was chromophobe RCC, nuclear grade G2 (par-
tial G1), and 1.7 cm × 1.5 cm × 1.5 cm in size (Fig. 1d); 
the tumor in the right kidney was clear-cell RCC, nuclear 
grade G2, and 5.0 cm × 4.7 cm × 4.5 cm in size (Fig. 1e).
Genomic DNA was extracted from blood samples col-
lected from the patient and his son. Mutation examina-
tion revealed that the proband and his son carried a 
deletion of two bases (AG) at nucleotides c.946-947 in 
exon 9 (c.946-947delAG) of the FLCN gene (Fig.  1f ), 
which caused a frameshift mutation starting at the 316th 
amino acid (p.316fs388x). No RCC was detected by 
abdominal CT scan on the son.
Case 2
A 37-year-old man presented with an asymptomatic right 
renal mass detected by ultrasonography and CT (Fig. 2a). 
No apparent cutaneous lesions were found by careful 
inspection and palpation of the skin. The patient had a 
history of spontaneous pneumothorax on both sides and 
underwent pulmonary bullectomy on the right side at the 
age of 30. His father had a history of recurrent spontane-
ous pneumothorax starting at the age of 28 and died of 
stoke at the age of 63. His uncle had a history of recurrent 
spontaneous pneumothorax starting at the age of 24 and 
died of an accident at the age of 56. Open partial nephrec-
tomy was performed on the patient. Histopathologic 
examination revealed that the tumor was chromophobe 
RCC, nuclear grade G2, and 2.2 cm × 2.0 cm × 2.0 cm in 
size (Fig. 2b).
Genomic DNA was extracted from blood samples col-
lected from the patient and his family members. Muta-
tion examination revealed that the proband carried a 
deletion of three bases (CCT) at nucleotides c.770-772 in 
exon 7 (c.770-772delCCT) (Fig. 2c), resulting in deletion 
of the 257th serine residue (p.257delS). No FLCN muta-
tions were found in any other members of the patient’s 
family.
Discussion
Most reported cases of BHD have been from Western 
countries, and reports of cases from Asia are rare, likely 
due to the lack of awareness and atypical manifestations 
of this disease in Asian patients. Identification of BHD 
patients is usually based on dermatologic signs. How-
ever, Kunogi et al. [6] found that among 30 Japanese BHD 
patients, only 6 (20.0%) had cutaneous lesions, 1 (3.3%) 
was histologically diagnosed with FFs, and 29 (96.7%) 
Fig. 1 Lesions and folliculin (FLCN) mutation in case 1. a Abdominal computed tomography (CT) scan with intravenous contrast reveals a renal 
mass in the upper pole of the left kidney (arrow). b Abdominal CT scan with intravenous contrast reveals a renal mass in the right kidney (arrow). c 
CT scan shows left pneumothorax (arrow). d Histopathology of the left renal tumor shows a monotonous cellular pattern with mild nuclear pleo-
morphism and abundant, partly eosinophilic cytoplasm with a perinuclear halo (chromophobe renal cell carcinoma). e Histopathology of the right 
renal tumor shows clear cytoplasm surrounded by a distinct cell membrane (clear cell carcinoma). f Both the patient and his son have a deletion 
of AG (c.946-947delAG) in exon 9 of the FLCN gene, which causes a frameshift mutation starting at the 316th amino acid (p.316fs388x). The deleted 
bases are underlined in the normal sequence
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had pneumothorax. Further, Furuya and Nakatani [7] 
reported that 13 (28.8%) patients had FFs, 40 (88.9%) 
had pulmonary cysts, and 9 (20.0%) had RCC among 
45 BHD patients from 19 Japanese families. In addition, 
Murakami et  al. [8] compiled 62 BHD cases from Asia 
and found that FFs were detected in 17 (27.4%), pulmo-
nary cysts in 49 (79.0%), and RCC in 11 (17.7%). In com-
parison, Toro et al. [9] found that among 51 BHD families 
in the United States, 46 (90.2%) had FFs, 45 (88.2%) had 
pulmonary cysts, and 25 (49.0%) had renal tumors. 
Kluger et al. [12] reported 22 patients from ten unrelated 
families with BHD in France; 18 (81.8%) patients had FFs, 
16 (72.7%) had pulmonary cysts or a history of pneu-
mothorax, and 10 (45.5%) had renal tumors. Therefore, 
the incidence of FFs may be lower among Asian BHD 
patients compared with the higher incidence of 80%–90% 
reported among patients from the United States and 
Europe, whereas the pulmonary cyst incidences are simi-
lar between patients from Asian and Western countries. 
FLCN mutation screening is recommended for patients 
with RCC and pulmonary cysts without cutaneous 
lesions, especially for those with a clear family history of 
RCC or pulmonary cysts/pneumothorax.
In this report, case 1 had two pathologic types (chromo-
phobe and clear-cell) of RCC. BHD patients are each likely 
to have various types of RCC [13], especially those with 
tumors with composite oncocytoma or chromophobe 
RCC histology [14]; these pathologies include the known 
familial hereditary RCCs, such as von Hippel-Lindau 
(VHL) syndrome, BHD syndrome, hereditary papillary 
renal cell carcinoma (HPRCC), hereditary leiomyomato-
sis renal cell carcinoma (HLRCC), and tuberous sclerosis 
complex (TSC). Pavlovich et al. [10] summarized clinical 
data of 124 BHD patients with 84 resected renal tumors, 
of which 56 (67%) were hybrid oncocytic tumors, 19 (23%) 
were chromophobe RCC, 6 (7%) were clear-cell RCC, and 
3 (4%) were renal oncocytoma. Urologists should thus be 
aware that the presence of chromophobe/oncocytic renal 
neoplasms, especially those that are bilateral or multifo-
cal, may indicate a diagnosis of BHD syndrome, even if 
dermatologic lesions are absent [11].
Over 100 unique mutations in the coding region of 
FLCN have been identified. Most of these mutations are 
frameshift, nonsense, insertion/deletion, or splice site 
mutations, resulting in truncation and inactivation of the 
encoded protein folliculin [15]. However, no clear geno-
type–phenotype associations between FLCN mutation 
type or location and skin, lung, or renal manifestations 
have been identified to date; only a significantly lower fre-
quency of renal neoplasia has been reported in patients 
with a deleted cytosine in the exon 11 mutational “hot 
spot” compared with the patients with an inserted cyto-
sine at this location [15, 16]. A definite diagnosis of BHD 
can only be made when a pathogenic germline FLCN 
mutation is detected. Detection of an FLCN gene muta-
tion not only confirms the diagnosis in suspected patients 
but also enables the diagnosis of at-risk family members 
with this disease. Once RCC is detected in BHD patients, 
it can be closely monitored as long as the dominant lesion 
is less than 3 cm in diameter. Surgical resection is recom-
mended when the solid lesion or solid portion of a mixed 
lesion exceeds the threshold diameter of 3  cm [10]. For 
patients with bilateral renal tumors measuring greater 
than 3  cm, staged surgeries in two separate settings are 
recommended [11]. The tumor growth rate and location 
are additional factors that should be considered [2, 11]. 
Recently, a kidney-specific knockout model was devel-
oped by disrupting mouse FLCN in proximal tubules 
[17]. This model provides a valuable tool for further study 
of FLCN-deficient renal tumorigenesis and for tests of 
new drugs (such as mTOR inhibitors) for the treatment 
of BHD-associated renal tumors.
Here, we report two Chinese patients with RCC and 
spontaneous pneumothorax who were diagnosed with 
Fig. 2 Lesion and FLCN mutation in case 2. a CT scan reveals a mass in the right kidney (arrow). b Histopathology of the resected tumor shows 
tumor cells with transparent, slightly reticulated cytoplasm with prominent cell membranes (chromophobe renal cell carcinoma). c The patient has 
a deletion of CCT (c.770-772delCCT) in exon 7 of the FLCN gene, which results in deletion of the 257th serine residue (p.257delS). The deleted bases 
are underlined in the normal sequence
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BHD syndrome. Both patients underwent FLCN gene 
mutation screening and were found to have two novel 
mutations (c.946-947delAG and c.770-772delCCT) that 
have not been reported previously. Importantly, skin FFs 
were absent in both patients. These findings demonstrate, 
particularly to urologists, the importance of performing 
FLCN gene mutation screening for patients with RCC 
and pulmonary cysts.
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